Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer by García-Alfonso, P et al.
Bevacizumab in combination with biweekly capecitabine and
irinotecan, as first-line treatment for patients with metastatic
colorectal cancer
P Garcı ´a-Alfonso*,1, AJ Mun ˜oz-Martin
1, S Alvarez-Suarez
1, Y Jerez-Gilarranz
1, M Riesco-Martinez
1,
P Khosravi
1 and M Martin
1
1Medical Oncology service, Hospital General Universitario Gregorio Maran ˜o ´n, C/ Doctor Equerdo, 46, Madrid 28007, Spain
BACKGROUND: Combination of capecitabine and irinotecan (XELIRI regimen) is an active and well tolerated treatment for metastatic
colorectal cancer (mCRC). The aim of this study was to evaluate the efficacy and safety of this regimen in combination with
bevacizumab (BV), as first-line treatment for mCRC.
PATIENTS AND METHODS: A total of 46 consecutive patients received a combination of BV (5mgkg
 1, day 1), irinotecan (175mgm
 2,
day 1) and capecitabine (1000mgm
 2 twice daily on day 2–8), every 2 weeks. Patients were treated until disease progression or
unacceptable toxicity. The primary objective was to determine the progression-free survival (PFS) and safety profile.
RESULTS: The overall response rate (ORR) was 67.4%, with a disease control rate (ORRþstable disease) of 93.5%. Median PFS and
overall survival (OS) were 12.3 months (95% confidence interval (CI): 6.5–18.1 months) and 23.7 months (95% CI: 16.7–30.6
months), respectively. The most frequent grade 3/4 treatment-related adverse events were asthenia (7%), diarrhoea (7%), nausea
(9%) and vomiting (7%).
CONCLUSION: Bevacizumab combined with biweekly XELIRI is a highly active first-line regimen for mCRC treatment, showing
encouraging PFS, ORR and OS with a good tolerability.
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Colorectal cancer (CRC) is the third most commonly diagnosed
malignancy and the second leading cause of cancer death in the
world, resulting in 4800000 deaths every year. In 2006, CRC
accounted for around 412900 cases, 12.9% of all reported cases of
cancer in Europe, being the second cause of cancer related death,
with 207400 (12.2%) deaths (Van Cutsem and Oliveira, 2009).
Overall, up to 20% of patients have metastatic disease at the
time of diagnosis, and B50–60% of patients will eventually
develop metastatic or advanced disease, with a poor 5-year survival
rate of 5%.
With the introduction in the last years of new regimens with
biological agents and different combinations of chemotherapy, the
progression-free survival (PFS) and overall survival (OS) have
substantially improved. Although a variety of combination
therapies have been studied and evaluated, the selection of the
first-line treatment for metastatic colorectal cancer (mCRC)
remains difficult, however, an optimum first-line approach
currently to be used would be either 5-fluorouracil/leucovorin plus
oxaliplatin or 5-fluorouracil/leucovorin plus irinotecan (FOLFIRI)
combined with a biological agent such as bevacizumab (BV).
Bevacizumab, a recombinant human monoclonal antibody
targeting vascular endothelial growth factor, was approved for
first-line treatment of patients with advanced CRC by the EMEA,
in early 2005, based on the data from the phase III AVF2107g trial
(Hurwitz et al, 2004), which showed an increased response rate
(RR), with an improved median duration of survival and a longer
median PFS.
As its introduction, fluoropyrimidine-based chemotherapy has
been the mainstay of chemotherapy treatment for CRC. Capeci-
tabine is an oral fluoropyrimidine that has similar efficacy to
5-fluorouracil/leucovorin (5-FU/LV) as first-line treatment of
advanced or mCRC (Hoff, et al, 2001; Van Cutsem et al, 2004),
with the advantage of convenient oral administration and
favourable safety profile (Scheithauer et al, 2003).
In xenograft models, the combination of BV and capecitabin
resulted in a synergistic effect, with a greater duration of tumour
inhibition than with either agent alone (Shen et al, 2004). Likewise,
in several phase I and II trials it has been observed that
capecitabine and irinotecan (XELIRI) can be equally effective,
and safely combined in the most convenient alternative XELIRI
regimen in patients with advanced CRC, with no pharmacokinetic
interactions reported (Tewes et al, 2003; Bajetta et al, 2004).
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sIn a previous clinical study on patients with mCRC, carried out
by our group in a biweekly combination of irinotecan and
capecitabine, was demonstrated that this schedule had a synergis-
tic effect, with an acceptable RR of 32% and good tolerability as
first-line treatment for mCRC, together with an important time to
progression of 9 months and an OS of 19.2 months in this
advanced setting. (Garcia-Alfonso et al, 2009).
Based on these premises, it is to be expected that the
combination of BV with this biweekly XELIRI scheme would be
at least as effective as the standard FOLFIRI regimen with an
expected good safety profile. The objectives of this study were to
evaluate the safety and the efficacy of this combination as first-line
treatment in patients with mCRC.
PATIENTS AND METHODS
Patients with histological or cytological confirmation of advanced
CRC were treated with BV plus XELIRI as first-line treatment in
one centre (Hospital General Universitario Gregorio Maran ˜o ´n,
Madrid, Spain). Signed informed consent was obtained from all
patients before starting treatment.
The primary objective was to determine the PFS, safety and
tolerability to the biweekly BV–XELIRI regimen. Secondary
objectives included overall response rate (ORR) and OS.
The study was conducted according to the Good Clinical
Practices and Declaration of Helsinki, and the Institutional Review
Board of the hospital approved this study.
Patient eligibility
Patients diagnosed with initially unresectable chemotherapy-naı ¨ve
mCRC were eligible. Main enrolment criteria were: age 18–75
years; presence of at least one unidimensionally measurable lesion;
Eastern Cooperative Oncology Group (ECOG) performance status
p2; adequate bone marrow function (neutrophil count
X1.5 10
9, platelets X100 10
9, haemoglobin X10gdl); serum
creatinine o1.25mgdl; alanine aminotransferase or aspartate
aminotransferase or alkaline phosphatase o2.5 times the upper
limit of normal or less than five times in the presence of liver
metastases. Previous adjuvant chemotherapy must have been
finished at least 6 months before enrolment in the study. Patients
were excluded if they had brain metastases, had inadequately
controlled hypertension, or had lack of physical integrity of
the upper gastrointestinal tract or malabsorption syndrome.
Because of the toxicities associated with BV, patients with
myocardial infarction within 1 year before start of treatment,
stroke, thromboembolic events, severe bleeding within 6 months
before treatment, haemorrhagic diathesis, non-healing wounds
or fractures or proteinuria X500mg/24h in urine sample were
excluded.
Treatment protocol
Patients were treated with BV 5mgkg
 1 on day 1, followed by
irinotecan 175mgm
 2 as a 30-min intravenous (i.v.) infusion on
day 1 and capecitabine 1000mgm
 2 orally twice daily; from day
2 to 8. All patients received 5-HT3 inhibitors for emesis prophylaxis.
Treatment was administered every 2 weeks and continued
until disease progression, patient refusal, unacceptable toxicity
or death.
Appropriate dose interruptions/reductions were implemented in
the event of specific toxicities, depending on their nature and
intensity. The next course of treatment only began when the
neutrophil count was 41.5 10
9, the platelet count was
4100 10
9, and any other treatment-related toxicities were less
than or equal to grade 1; otherwise, treatment was withheld for up
to 2 weeks. If adverse events did not improve to grade 0 or 1 after
3 weeks, patients were discontinued from study. For grade 2–3
hand–foot syndrome, the capecitabine treatment was withheld
until a resolution to less than or equal to grade 1, the second time
this toxicity occurs treatment was restarted with a 25% dose
reduction.
Study assessments
A screening assessment including medical history, physical
examination and a chest X-ray was conducted within 2 weeks
before starting the treatment. Within 7 days before starting the
treatment, further assessments included vital signs, ECOG
performance status and laboratory tests (haematology; blood
chemistry including liver and renal function test; and urinalysis).
A computerised tomography scan of chest, abdomen and pelvis
was completed within 4 weeks of starting the treatment. The
assessment of response was based on investigator reported
measurements according to Response Evaluation Criteria in Solid
Tumours guidelines (Therasse et al, 2000). CR or PR patients were
required to undergo a confirmatory disease assessment at least
4 weeks later.
Statistical considerations
Descriptive statistics were reported as proportion and medians.
Progression-free survival was defined as the period from the date
of the first dose of study treatment to the first observation of
disease progression or death by any cause. The OS was calculated
as the period from the date of the first cycle of treatment until
death of any cause or until the date of the last follow-up, at which
data point was censored. Survival analysis (PFS and OS) was
estimated by the Kaplan–Meier method (Kaplan and Meier, 1958).
Safety was assessed in terms of toxicity and evaluated according
to the NCI-Common Toxicity Criteria for Adverse Events (NCI-
CTCAE), version 3.0. All analyses were performed using SPSS 11.5
for Windows (Chicago, IL, USA).
RESULTS
A total of 46 consecutive patients treated with BV plus biweekly
XELIRI were included. Baseline characteristics for the evaluable
patients are summarised in Table 1. Median age was 64 years
(range 39–80). In all, 45 (98%) patients had an ECOG performance
status of o2 at baseline, half of patients had multiple sites of
metastases and these were mostly located in the liver (65%).
Toxicity and dose administration
A total of 586 cycles of chemotherapy plus BV were administered
with a median of 12 cycles per patient (range 1–35). Overall, 41%
(n¼19) of patients required at least one dose reduction of
capecitabine and in 50% (n¼23) treatment delay was needed; dose
of irinotecan was reduced in 37% (n¼17) of patients and delayed
in 52% (n¼24). There were no dose reductions of BV, but in 54%
of the patients the administration was delayed at least once.
Treatment interruption because of toxicity caused by capecitabine,
irinotecan and BV was required in two, four and four patients,
respectively.
Treatment was well tolerated and most of the adverse events
reported were mild (NCI-CTCAE grade 1 or 2). The main
haematology and non-haematology toxicities are summarised in
Table 2. The most common grade 3–4 toxicities were: nausea
(8.7%), diarrhoea (6.5%), vomiting (6.5%), arterial thrombosis
(4.3%), hand-foot skin reaction (2.2%), hypertension (2.2%),
intestinal obstruction (2.2%), neutropenia (2.2%) and hyperbili-
rubinemia (2.2%). Two cases of pulmonary thromboembolism led
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sto continuation of therapy only without BV. No treatment-related
deaths were reported.
Efficacy and survival
The BV plus biweekly XELIRI regimen led to an objective response
in 31 out of 46 (67%) patients of whom 4% had a CR and 63% had
a PR. A further 12 (26%) patients had stable disease resulting in a
disease control rate of 93% (Table 3). In this initially unresectable
population, 13 patients (28%) underwent surgical removal of
metastases after the treatment with chemotherapy plus BV, with
curative intention in 4 patients with liver involvement only and in
2 with extrahepatic metastases; 7 patients were able to undergo
a secondary tumour resection in terms of palliative therapy.
The median time elapsed between the last administration of BV
and surgery was 10.4 weeks. After a median follow-up of 15.8
months, 37 (80%) patients had progressed and the median
duration of PFS was 12.3 months (95% confidence interval (CI):
6.5–18.1; Figure 1). So far, 23 (50%) patients have died, and
median OS is 23.7 months (95% CI: 16.7–30.6 months; Figure 2).
DISCUSSION
Nowadays, there are multiple options for the treatment of mCRC
that include different chemotherapeutic agents and biologics.
Great effort has been made over the last years to improve the
efficacy and safety of the chemotherapy combinations and to find
new alternatives by combining the new biological agents with the
classic regimens.
Table 2 Most common treatment-related adverse events per patient
Grade 1/2 Grade 3/4 Total
N % N % N %
Diarrhoea 29 63 3 7 32 70
Asthenia 28 61 3 7 31 67
Nausea 26 57 4 9 30 65
Vomiting 22 48 3 7 25 54
Alopecia 19 41 6 13 25 54
Mucositis 20 44 1 2 21 46
Anaemia 20 43.5 — — 20 44
Hand–foot skin reaction 17 37 1 2 18 39
Bleeding 17 37 — — 17 37
Constipation 7 15 2 4 9 20
Neutropenia 6 13 1 2 7 15
Proteinuria 6 13 — — 6 13
Epigastralgia 6 13 — — 6 13
Anorexia 5 11 — — 5 11
Headache 5 11 — — 5 11
Fever 5 11 — — 5 11
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Figure 1 Kaplan–Meier estimates of progression-free survival.
70 60 50 40 30 20 10 0
Time (months)
1.0
0.8
0.6
0.4
0.2
0.0
O
v
e
r
a
l
l
 
s
u
r
v
i
v
a
l
Censored
Figure 2 Kaplan–Meier estimates of overall survival.
Table 1 Baseline patient characteristics
Characteristic Number of patients (%)
Patients 46
Median age (years; range) 64 (39–80)
Sex
Male 21 (46)
Female 25 (54)
ECOG PS
0 7 (15)
1 38 (83)
2 1 (2)
Previous therapy
Surgery 16 (35)
Radiation 14 (30)
Chemotherapy 12 (26)
Number of metastatic sites
1 20 (43.5)
2 20 (43.5)
X3 6 (13)
Metastatic site(s)
Liver 30 (65)
Lung 18 (39)
Lymph node(s) 17 (37)
Peritoneum 6 (13)
Other 7 (15)
Abbreviation: ECOG PS¼Eastern Cooperative Oncology Group performance
status.
Table 3 Best response to treatment
XELIRI plus bevacizumab (%)
Complete response 2 (4)
Partial response 29 (63)
Objective response 31 (67)
Progressive disease 12 (6.5)
R0 resection 6 (13)
Abbreviation: XELIRI¼capecitabine and irinotecan.
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sThe addition of BV, a novel antiangiogenic drug, to the
irinotecan/5-fluorouracil/leucovorin scheme (IFL regimen) in
first-line treatment of mCRC has been reported to improve OS,
PFS, objective RR and duration of response compared with IFL
alone (Hurwitz et al, 2004). Recently, Fuchs et al (2008) reported
that infusional 5-FU/LV with irinotecan and BV conferred a
statistically significant OS when compared with bolus irinotecan
and 5-FU/LV (modified IFL; 28.0 months vs 19.2 months;
P¼0.037; HR for death¼1.79; 95% CI: 1.12–2.88), with diarrhoea
as the main common dose-limiting toxicity.
Data from several trials have shown that 5-FU/LV regimen could
be substituted by the orally administered fluoropyrimidine
capecitabine when capecitabine-based combinations have been
compared with the equivalent 5-FU/LV-based regimens. In terms
of OS, capecitabine is at least equivalent to 5-FU/LV with the added
benefits of convenience and a favourable safety profile. A phase III
trial with previously untreated mCRC patients randomised to
either oral capecitabine or i.v. bolus 5-FU/LV (Mayo Clinic
regimen) demonstrated a significantly superior RR of capecitabine
compared with 5-FU/LV (26 vs 17%; Po0.0002). Overall survival
in the two treatment arms was equivalent (median of 12.9 months
with capecitabine vs 12.8 months with 5-FU/LV; Van Cutsem et al,
2004). The combination of capecitabine with irinotecan (XELIRI)
has been shown to be more active than either drug alone. In our
previous phase II study, in which patients with mCRC received
capecitabine at 1000mgm
 2 twice daily (days 2–8) plus irinotecan
at 175mgm
 2 (day 1) in a 15-day cycle, XELIRI combination
yielded a 32% ORR and a median time to tumour progression of
9.9 months. Disease control was achieved in 66% of evaluable
patients. The XELIRI regimen was relatively well tolerated, with the
most common grade 3/4 toxicities being diarrhoea (15%) and
neutropenia (8%) (Garcia-Alfonso et al, 2009). The fact that
capecitabine is generally well tolerated makes it suitable for
combination with other cytotoxics. Cassidy et al (2004), found that
capecitabine plus oxaliplatin achieved consistently high (450%)
RRs across all patient sub-populations.
In spite of these encouraging results, in the BICC-C (Bolus,
Infusional, or Capecitabine with Camptosar-Celecoxib) and
EORTC 40015 phase III trials of XELIRI regimens, with and
without targeted-agents, some concern about toxicity arose
because of the greater proportion of GI events on the XELIRI
arm (Fuchs et al, 2007; Ko ¨hne et al, 2008).
The standard schedule for capecitabine as monotherapy is
1250mgm
 2 twice daily for 14 days followed by 7 days off (14/7),
however, from mathematical models and breast cancer xenografts
studies, it is suggested that the greatest effect is achieved after B7
days of treatment and that a continued administration longer than
7 days adds toxicity, but no additional efficacy. Kolinsky et al,
carried out an experimental study to determine the antitumor
activity and tolerability of capecitabine administered using either a
schedule of 7 days of treatment followed by 7 days drug-free (7/7)
or 14/7 days, alone and in combination with irinotecan and BV.
The authors concluded that the addition of BV to XELIRI
significantly improved tumour growth inhibition and life span in
the model studied and that modified capecitabine schedule
improved the efficacy of doublet and triplet combinations without
adding toxicity (Traina et al, 2008; Kolinsky et al, 2009).
To date, there have been limited data about the XELIRI plus BV
regimen. Chen et al (2009), presented the preliminary results from
a study using BV with irinotecan plus capecitabine, and they
showed that this combination had promising clinical activity. They
found an ORR of 40%, with an overall disease control rate of 86%
and a 1-year progression-free rate of 49%.
At the 2009 Annual Meeting of the American Society of Clinical
Oncology (ASCO), Ducreux et al (2009), reported the preliminary
results of the phase II, non-comparative, randomised FNCLCC
ACCORD 13/0503 trial, in which a total of 145 patients, from 18 to
72 years of age, were randomised to receive either BV plus XELIRI
(irinotecan 200mgm
 2 on day 1, capecitabine 1000mgm
 2 twice
daily on days 1–14 plus BV 7.5mgkg
 1 on day 1, every 3 weeks) or
BV plus FOLFIRI (irinotecan 180mgm
 2 on day 1 plus 5-FU
400mgm
 2 plus leucovorin 400mgm
 2 on day 1 followed by 5-FU
2400mgm
 2 as a 46-hour infusion plus BV 5mgkg
 1 on day 1,
every 2 weeks). The preliminary results from the first 6-month
follow-up reported an ORR of 58% (95% CI: 47–70%) in the BV
plus XELIRI arm similar to 58% (95% CI: 53–65%) in the BV plus
FOLFIRI arm. The most common grade 3–4 adverse events
reported in the XELIRI and FOLFIRI groups were neutropenia (17
vs 26%), diarrhoea (12 vs 5%) and cardiovascular events (13 vs
11%). The investigators concluded that XELIRI and FOLFIRI plus
BV are both similarly effective in the treatment of patients with
mCRC, with manageable toxicity.
In this single-institutional study, with the combination of
biweekly XELIRI plus BV for previously untreated mCRC patients,
we observed a meaningful clinical activity, with an ORR of 67.4%, a
median PFS of 12.3 months, and a median OS of 23.7 months. The
overall disease control rate was 93.5%. In general, this combination
was relatively well tolerated, with most of the adverse events being
grade 1–2. Interestingly, the overall safety profile of this
combination differs from those reported with the XELIRI regimen
by Fuchs. In the BICC-C trial, the XELIRI arm was associated with
a significantly higher incidence of grade 3/4 diarrhoea (48%),
neutropenia (32%) and dehydration (19%; Fuchs et al, 2007). In
the 40015 clinical trial conducted by EORTC group, XELIRI was
associated with increased mortality as well as a nearly 40%
incidence of grade 3/4 diarrhoea (Ko ¨hne et al, 2008). In these two
clinical trials, the increased toxicity clearly impacted the clinical
activity of the XELIRI regimen in a negative manner. However, it is
noteworthy that the doses of XELIRI used in these studies were
higher than the ones used in this XELIRI plus BV combination.
Compared with the recent findings of the Ducreux’s trial, which
investigated the combination of XELIRI and FOLFIRI along with BV,
the clinical activity of the data here reported in terms of ORR was
similar to what has been reported for the FNCLCC ACCORD 13/0503
trial, with a better toxicity profile, possibly due to the lower dose of
chemotherapeutic agents in this XELIRI plus BV regimen.
Our analyses show that the combination of BV with the XELIRI
regimen is feasible with manageable toxicity, and that is associated
with a promising efficacy in terms of PFS, ORR and OS in
previously untreated mCRC.
CONCLUSION
In summary, this study suggests that a biweekly schedule of
capecitabine plus BV is a promising regimen that should be considered
as a one of the front-line standards of care for patients with mCRC.
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